Publications

Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

By:
Contributors: Bryan Donnelly, MD, MSc, FRCSC, Dean Ruether, MD FRCSC, Michael Chetner, MD, MSc, FRCSC, FACS, Peter Venner, MD, FRCPC
Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.

Abstract

Screening for prostate cancer remains a contentious issue. As with other cancer screening programs, a key feature of the debate is verification of cancerspecific mortality reductions. Unfortunately the present evidence, two systematic reviews and six randomized controlled trials, have reported conflicting results. Furthermore, half of the studies are poor quality and the evidence is clouded by key weaknesses, including poor adherence to screening in the intervention arm or high rates of screening in the control arm. In high quality studies of prostate cancer screening (particularly prostatespecific antigen), in which actual compliance was anticipated in the study design, there is good evidence that prostate cancer mortality is reduced. The numbers needed to screen are at least as good as those of mammography for breast cancer and fecal occult blood testing for colorectal cancer. However, the risks associated with prostate cancer screening are considerable and must be weighed against the advantage of reduced cancerspecific mortality. Adverse events include 70% rate of false positives, important risks associated with prostate biopsy, and the serious consequences of prostate cancer treatment. The best evidence demonstrates prostate cancer screening will reduce prostate cancer mortality. It is time for the debate to move beyond this issue, and begin a well-informed discussion on the remaining complex issues associated with prostate cancer screening and appropriate management.

table

 PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

We are excited to announce the recent online publication of PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks in the Journal of Clinical Oncology-Clinical Cancer Informatics!

PROSPeCT is a user-friendly online clinical information system that offers an easy and efficient way to obtain relevant and accurate information about patients from APCaRIs robust and expanding database. If you use PROSPeCT already then please cite this article in your work. If you do not use PROSPeCT yet then read this article for more details about easy-to-use and powerful query tool! Thank you to the Alberta Cancer Foundation, plus others, for supporting this project.

Citation
PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks
Maria Cutumisu, Catalina Vasquez, Maxwell Uhlich, Perrin H. Beatty, Homeira Hamayeli-Mehrabani, Rume Djebah, Albert Murtha, Russell Greiner, and John D. Lewis
JCO Clinical Cancer Informatics 2019 :3, 1-12 DOI: 10.1200/CCI.18.00144

2019.05 Cutumisu et al PROSPeCT JCO CCI

- Unknown